Business Wire

NetWitness Launches Comprehensive XDR Offerings for Next Generation Security

7.6.2022 19:00:00 EEST | Business Wire | Press release

Share

NetWitness, a globally trusted provider of cybersecurity technologies and incident response, today announced NetWitness XDR, a family of products and capabilities delivering comprehensive detection and response on premise, in the cloud or as a hybrid of the two. This new offering and product architecture delivers the full range of deployment options enterprises seek today to meet their unique cybersecurity needs and use cases.

NetWitness XDR delivers a robust set of capabilities enabling extended detection and response (XDR) and helping customers stay ahead of the most sophisticated cyber threats. These include:

  1. Unified collection, data, and visibility across multiple security layers
  2. Automatic enrichment of data using any technical or business source
  3. A wide toolset of detection technologies including, but not limited to, advanced behavioral analysis
  4. External and internal threat intelligence to identify known security risks and threat actors
  5. Truly insightful context, visualization, and investigation tools
  6. Threat hunting tools and methodologies to identify previously unknown threats
  7. Highly repeatable and measurable incident investigation and response processes
  8. A strong array of both automated and human response options

“NetWitness has enjoyed the trust of some of the world’s most security sensitive organizations because of its unique ability to monitor the entire attack surface across the network, endpoint, cloud, IoT, logs and more,” said CEO of RSA and NetWitness, Rohit Ghai. “We have been delivering XDR capability to the market for several years and today we are delighted to announce new innovations in the platform and reintroduce it to the market as NetWitness XDR.”

Under this new model, NetWitness XDR will be comprised of three main product lines that showcase its uniquely powerful support for all XDR use cases. NetWitness Platform XDR 12 is the newest major release of NetWitness Platform. This technology stack, typically deployed as customer-managed software or hosted by MSSPs, has been enhanced to focus on detection capabilities that identify threats faster and decrease their impact. The company’s new cloud-native SaaS version will be known as NetWitness Vision XDR and is currently in design preview. The third product line, NetWitness XDR Cloud Services, is a set of optional SaaS applications that take advantage of the cloud’s inherent elastic nature to deliver flexible and cost-effective components which can be used to augment either Platform XDR or Vision XDR.

“Our network-forward approach allows us to stand out in this emerging space and highlights NetWitness XDR’s ability to detect across customers’ growing number of systems and devices,” said Director of Product Management and Research, Kevin Bowers. “We are embracing the belief that the best XDR must be consumable on prem, in the cloud, and hybrid.”

Developed initially in 1996, NetWitness began as a government-sponsored research project to inspect network packets for cyberthreats and tools to detect and respond to them. Since then, the technology has continuously evolved and been innovated to tackle today’s most complex attacks. NetWitness now features fully integrated components for network, log, endpoint and IoT detection and response that drive its threat intelligence and security orchestration platform, NetWitness Orchestrator. With its long history and global footprint, NetWitness XDR integrates directly with the world’s most critical and widely deployed tools, as well as many specialized and industry-specific solutions.

NetWitness XDR will host demonstrations at its booth at RSA Conference this year for Platform XDR and Vision XDR.

To learn more, visit www.netwitness.com.

ABOUT NetWitness

NetWitness, an RSA® Group Business, provides comprehensive and highly scalable threat detection and response capabilities for organizations around the world. The NetWitness Platform delivers complete visibility combined with applied threat intelligence and user behavior analytics to detect, prioritize, investigate threats, and automate response. This empowers security analysts to be more efficient and stay ahead of business-impacting threats. For more information, visit netwitness.com.

©2022 RSA Security LLC or its affiliates. All rights reserved. RSA and the RSA logo are trademarks of RSA Security LLC or its affiliates. For a list of RSA trademarks visit https://www.rsa.com/en-us/company/rsa-trademarks . Other trademarks are trademarks of their respective owners. RSA believes the information in this document is accurate. The information is subject to change without notice.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

SHIFT Communications
netwitness@shiftcomm.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 12:00:00 EEST | Press release

Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely with healthcare authorities and other stakeholders to support timely access for people with Parkinson’s disease who continue to experience moderate to severe motor fluctuations despite current oral therapies. Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. Despite availab

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 11:16:00 EEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 11:00:00 EEST | Press release

Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich, the findings show that the clinically relevant reductions in low-density lipoprotein cholesterol (LDL-C) achieved within the first year of treatment are estimated to translate into clinically meaningful reductions in 10-year cardiovascular (CV) risk.1 The data further reinforce the clinical value of bempedoic acid, and its fixed-dose combination with ezetimibe, across a diverse range of patient subtypes, regardless of gender and glycaemic profile (diabetes, pre-diabetes, or normoglycemia).2,3 Key findings from the new analyses of the MILOS study include: 10-year CV risk estimate reduction: An analysis of 960 at-risk patients estimated that one year of bempedoic acid-add-on ther

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 10:31:00 EEST | Press release

TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a tremendous leader and played a pivotal role in the growth of TVS Motor Company. The leadership transition comes as TVS Motor Company builds on strong business performance and continues to consolidate its position in India and expand its global presence. In FY2025-26, the company achieved a record performance, selling 5.9 million vehicles globally and delivering 30% revenue growt

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 22:27:00 EEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye